AZTA vs BIO: fair value comparison
Azenta, Inc. and Bio-Rad Laboratories, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BIO currently sits closer to the top of our ranking by discount to fair value. BIO carries the stronger quality grade.
| AZTA | BIO | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $34.09 | $355.57 |
| 12-month range | $16.02–$42.73 | $241.71–$390.34 |
| Rank by discount to fair value | #107 of 108 Healthcare | #80 of 108 Healthcare |
| Quality grade | D | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AZTA fair value analysis · BIO fair value analysis